Please login to the form below
Healthcare terms - L
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare terms - L
- Labelling
- Ladder of loyalty
- Latent click through
- Latent demand
- Launch
- Launch plan
- Layout
- Lead generation
- Lead management
- Leader article
- Leader pricing
- Learning curve
- Learning log
- License (product)
- License agreement
- Licensed
- Life cycle (product)
- Lifestyle
- Lifestyle drug
- Lifestyle research
- Likert scale
- Line extension
- List broker
- List building
- List price
- Literature search
- Loaded question
- Lobby
- Lobby firm
- Local advertising
- Logistics
- Logo
- Long term value (LTV)
- Long-range planning
- Loss leader
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
-
CEO Pricing & Market Access, UK
-
Six figure salary
-
CEO, Head of Health, UK
-
Six figure salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Valneva COVID-19 vaccine more effective than AZ
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Merck receives first breast cancer approval in Europe for Keytruda
- Benefits of COVID-19 vaccine in younger children outweigh risks, says FDA
- Call for industry innovators to join working group
- Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19
- US COVID-19 booster programme expanded
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Curb your conservatism: can pharma ditch its cautious approach to creativity in comms?
- Breaking the silence: It’s time to talk about the menopause
- Valneva COVID-19 vaccine more effective than AZ
- Early knockback for AbbVie as FDA rejects Allergan eye drug
PMHub
Frontera Group
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...
